<p>CK-165 decreased RSVP following intratracheal nebulization of 30 mg/kg in rats with monocrotaline induced pulmonary artery hypertension by 18.0±3.8% (p<0.05) when compared with vehicle treated group. The decrease is similar to that in monocrotaline rats treated with 100 mg/kg/day sildenafil (20.3±4.5%) for 7 days and treatment with CK-165 does not appear to have additive effects when co-administered with sildenafil.</p
PurposePulmonary arterial hypertension (PAH) leads to right ventricular failure (RVF) as well as an ...
Selective pulmonary vasodilators attenuate acute pulmonary embolism (APE)-induced pulmonary hyperten...
Phosphodiesterase type-5 (PDE-5) inhibitors are novel and important options for the treatment of pul...
Sildenafil, a phosphodiesterase 5 inhibitor, is currently under investigation for therapy of pulmona...
<p>CK-165 decreased RVSP rapidly after nebulization at both 5 mg/kg and 30 mg/kg by 20.4±8.6 and 58....
Sildenafil, an oral phosphodiesterase Type 5 inhibitor, has vasodilatory effects through a cGMP-depe...
There is considerable interest in the pleiotropic effects of statins and their potential role in the...
Release of fat and bone marrow during medullary pressurisation leads to fat embolism and pulmonary h...
Treatment of pulmonary hypertension has not yet been established and effective drug therapies are re...
ABSTRACT: Statins have been proposed to be a potential treatment for pulmonary arterial hypertension...
We assessed the effects of lodenafil on hemodynamics and inflammation in the rat model of monocrotal...
Abstract only availableFaculty Mentor: Dr. Vincent DeMarco, Child HealthBackground: Pulmonary arteri...
[[sponsorship]]分子生物研究所[[note]]已出版;[SCI];有審查制度;具代表性[[note]]http://gateway.isiknowledge.com/gateway/Ga...
Pulmonary hypertension (PH) is characterized by enhanced pulmonary vascular resistance, which causes...
Background and purpose: Phosphodiesterase-5 inhibitors are beneficial in pulmonary hypertension and ...
PurposePulmonary arterial hypertension (PAH) leads to right ventricular failure (RVF) as well as an ...
Selective pulmonary vasodilators attenuate acute pulmonary embolism (APE)-induced pulmonary hyperten...
Phosphodiesterase type-5 (PDE-5) inhibitors are novel and important options for the treatment of pul...
Sildenafil, a phosphodiesterase 5 inhibitor, is currently under investigation for therapy of pulmona...
<p>CK-165 decreased RVSP rapidly after nebulization at both 5 mg/kg and 30 mg/kg by 20.4±8.6 and 58....
Sildenafil, an oral phosphodiesterase Type 5 inhibitor, has vasodilatory effects through a cGMP-depe...
There is considerable interest in the pleiotropic effects of statins and their potential role in the...
Release of fat and bone marrow during medullary pressurisation leads to fat embolism and pulmonary h...
Treatment of pulmonary hypertension has not yet been established and effective drug therapies are re...
ABSTRACT: Statins have been proposed to be a potential treatment for pulmonary arterial hypertension...
We assessed the effects of lodenafil on hemodynamics and inflammation in the rat model of monocrotal...
Abstract only availableFaculty Mentor: Dr. Vincent DeMarco, Child HealthBackground: Pulmonary arteri...
[[sponsorship]]分子生物研究所[[note]]已出版;[SCI];有審查制度;具代表性[[note]]http://gateway.isiknowledge.com/gateway/Ga...
Pulmonary hypertension (PH) is characterized by enhanced pulmonary vascular resistance, which causes...
Background and purpose: Phosphodiesterase-5 inhibitors are beneficial in pulmonary hypertension and ...
PurposePulmonary arterial hypertension (PAH) leads to right ventricular failure (RVF) as well as an ...
Selective pulmonary vasodilators attenuate acute pulmonary embolism (APE)-induced pulmonary hyperten...
Phosphodiesterase type-5 (PDE-5) inhibitors are novel and important options for the treatment of pul...